Try our beta test site

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2008 by University of California, Los Angeles.
Recruitment status was:  Recruiting
United Therapeutics
Information provided by:
University of California, Los Angeles Identifier:
First received: June 23, 2008
Last updated: June 24, 2008
Last verified: June 2008
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.

Condition Intervention Phase
Pulmonary Arterial Hypertension
Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis
Drug: treprostinil
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease

Resource links provided by NLM:

Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • 6 minute walk distance [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Hemodynamic parameters [ Time Frame: 3 months ]
  • Quality of life and shortness of breath indices [ Time Frame: 3 months ]

Estimated Enrollment: 20
Study Start Date: January 2008
Estimated Study Completion Date: February 2009
Estimated Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: I
Patients with idiopathic pulmonary fibrosis with severe pulmonary arterial hypertension
Drug: treprostinil
For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min per day initially as tolerated and then increased by 0.5ng/kg/min every 2 days as an outpatient. The maximum dose at 3 months will be 40ng/kg/min


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Eligible subjects must have IPF and severe PAH documented on standard of care right-heart catheterization (RHC) and planned to receive therapy with treprostinil as recommended by the treating physician.

  1. All subjects must have high resolution CT scan (HRCT) diagnostic of IPF (performed as part of standard of care evaluation) or if available, biopsy proven histological usual interstitial pneumonia (UIP).
  2. Severe pulmonary arterial hypertension defined as a resting mean pulmonary artery pressure (mPAP) > 35 mm Hg; AND pulmonary vascular resistance (PVR) > 3 woods-units; AND pulmonary capillary wedge pressure (PCWP) < 18 mm Hg by right-heart catheterization (RHC) performed as part of standard of care evaluation.
  3. All subjects must be planned to receive treprostinil therapy as recommended by their treating physician.

Exclusion Criteria:

  1. Acute or chronic impairment other than dyspnea (e.g. angina pectoris, intermittent claudication) limiting the ability to perform standard of care six-minute walk tests (6MWT).
  2. Six-minute walk distance (6MWD) < 50 meters at screening or baseline standard of care evaluations
  3. Standard of care pulmonary function test (PFT) showing forced expiratory volume in one second (FEV1)/ forced vital capacity (FVC) ratio < 0.65
  4. Standard of care pulmonary function test (PFT) showing a residual volume >120% predicted
  5. Standard of care high-resolution chest computed tomography (HRCT) showing emphysema extent > 30%
  6. Any investigational therapy as part of a clinical trial for any indication with 30 days before screening
  7. Change in dose of treatment for IPF - investigational agent (gamma interferon-1b, pirfenidone, etanercept, and any other investigational agent intended to treat IPF), corticosteroids, or cytotoxic agents, within 30 days before screening. That is, subjects can be on any of these agents provided the dose is stable for at least 30 days prior to enrollment.
  8. Current treatment for pulmonary hypertension with other prostaglandins (epoprostenol or iloprost)
  9. Change in dose of treatment for PAH - (bosentan, sitaxsentan, ambrisentan, tadalafil, sildenafil, vardenafil, calcium channel blockers, nitrates, digitalis), within 30 days before screening. That is, subjects can be on any of these agents provided the dose is stable for at least 30 days prior to enrollment
  10. Pulmonary rehabilitation initiated within 30 days of baseline.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00705133

United States, California
David Geffen School of Medicine, UCLA
Los Angeles, California, United States, 90095
Sponsors and Collaborators
University of California, Los Angeles
United Therapeutics
Principal Investigator: Rajan Saggar, MD David Geffen School of Medicine, UCLA
Principal Investigator: David Zisman, MD David Geffen School of Medicine, UCLA
  More Information

Responsible Party: Rajan Saggar MD, David Geffen School of Medicine, University of California, Los Angeles Identifier: NCT00705133     History of Changes
Other Study ID Numbers: 07-11-087-01 
Study First Received: June 23, 2008
Last Updated: June 24, 2008

Keywords provided by University of California, Los Angeles:
pulmonary hypertension
pulmonary fibrosis
interstitial lung disease

Additional relevant MeSH terms:
Lung Diseases
Hypertension, Pulmonary
Pulmonary Fibrosis
Familial Primary Pulmonary Hypertension
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Respiratory Tract Diseases
Antihypertensive Agents processed this record on February 17, 2017